The company has a superior market capital essence in the cannabis industry. How do you describe the strategy behind this outcome?
When I started the company, the regulations were evolving, and the intentions were clear; certain jurisdictions would end prohibition. We created a culture where there would be no shortcuts, no cheating. We hired brilliant people, specifically those who had the potential to collaborate. Canopy Growth Corporation seeks to get extremely bright people together.
How do you assess the medical cannabis industry in Jamaica?
The industry started off early and then became fairly quiet for a year or two. We now see a great deal of acceleration again. When I was working with all of the facilities, I saw 80% of alignment with the way the sector is regulated in Canada.
How do Jamaicans contribute to the expansion of the corporation?
We have an entity here that we have invested in. As a result, our Jamaica connection is that many people get the opportunity to work on medical research. There is cohort of people in Jamaica that is significantly more receptive to the idea that there could be geriatric remedies that will simply look at improving appetites and reducing anxiety as people age. We have done medical studies here, and this can be a great place for us to continue our operations.
What are your goals for 2019?
Canopy Growth Corporation is wrapping up the year, though it has to get recreational products across Canada. There are certain countries that are participating in the market, and there are 12 other countries that are federally turning it on, from Colombia to Denmark. There will be many projects wrapping up in Canada that need to be done. As well, we will have to look at developments in the US and the EU in 2019.